English Polski
Vol 28, No 2 (2022)
Letter to the Editor
Published online: 2022-08-16

open access

Page views 3898
Article views/downloads 340
Get Citation

Connect on Social Media

Connect on Social Media

Commentary to the guidelines: “Guidelines on the prevention and treatment of venous thromboembolism in cancer patients treated surgically, including patients under 18 years of age”

Zbigniew Krasiński, Beata Krasińska
Acta Angiologica 2022;28(2):35-38.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5(3): 632–634.
  2. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2): 315–352.
  3. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020; 38(5): 496–520.
  4. Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Natl Compr Canc Netw. 2015; 13(9): 1079–1095.
  5. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018; 16(9): 1891–1894.
  6. Konstantinides SV, Meyer G, Becattini C, et al. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019; 54(3).
  7. Farge D, Frere C, Connors JM, et al. International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019; 20(10): e566–e581.
  8. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021; 5(4): 927–974.
  9. Heidbuchel H, Verhamme P, Alings M, et al. ESC Scientific Document Group, European Heart Rhythm Association. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013; 34(27): 2094–2106.
  10. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17(10): 1467–1507.
  11. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
  12. Yang M, Li J, Sun R, et al. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis. J Cancer Res Ther. 2019; 15(7): 1541–1546.
  13. Streiff MB, Milentijevic D, McCrae K, et al. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol. 2018; 93(5): 664–671.
  14. Alok A. Khorana, MD, Keith McCrae, MD, Dejan Milentijevic, Nora McCormick, François Laliberté, Concetta Crivera, Patrick Lefebvre, MA, Dominique Lejeune, Heather Rozjabek, Jeff Schein, Michael B. Streiff, VTE Recurrence and Safety of Anticoagulants Among Patients with Cancer Treated for Venous Thromboembolism, Blood. 2017; 130(Supplement 1): 4631.